Bonjesta Patent Expiration

Bonjesta is a drug owned by Duchesnay Inc. It is protected by 5 US drug patents filed from 2017 to 2018. Out of these, 4 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 18, 2033. Details of Bonjesta's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937132 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(8 years from now)

Active
US9375404 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(8 years from now)

Active
US9526703 Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(8 years from now)

Active
US9089489 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Feb, 2033

(8 years from now)

Active
US7560122 Pharmaceutical dosage form bearing pregnancy-friendly indicia
Jan, 2019

(5 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bonjesta's patents.

Given below is the list of recent legal activities going on the following patents of Bonjesta.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Yr, Small Entity 15 Jan, 2024 US9526703
Payment of Maintenance Fee, 8th Yr, Small Entity 26 Jul, 2023 US9375404
Payment of Maintenance Fee, 8th Yr, Small Entity 12 Dec, 2022 US9089489
Payment of Maintenance Fee, 4th Yr, Small Entity 29 Sep, 2021 US9937132
Expire Patent 16 Aug, 2021 US7560122
Maintenance Fee Reminder Mailed 01 Mar, 2021 US7560122
Payment of Maintenance Fee, 4th Yr, Small Entity 09 Apr, 2020 US9526703
Payment of Maintenance Fee, 4th Yr, Small Entity 29 Jul, 2019 US9375404
Payment of Maintenance Fee, 4th Yr, Small Entity 01 Nov, 2018 US9089489
Patent Issue Date Used in PTA Calculation 10 Apr, 2018 US9937132

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Bonjesta is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Bonjesta's family patents as well as insights into ongoing legal events on those patents.

Bonjesta's Family Patents

Bonjesta has patent protection in a total of 30 countries. It's US patent count contributes only to 10.2% of its total global patent coverage. Click below to unlock the full patent family tree for Bonjesta.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Bonjesta's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 18, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Bonjesta Generics:

Doxylamine Succinate; Pyridoxine Hydrochloride is the generic name for the brand Bonjesta. 4 different companies have already filed for the generic of Bonjesta, with Actavis Labs Fl Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Bonjesta's generic

How can I launch a generic of Bonjesta before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Bonjesta's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Bonjesta's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Bonjesta -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
20 mg/20 mg 28 Aug, 2018 1 01 Mar, 2022 18 Feb, 2033 Deferred

Alternative Brands for Bonjesta

Bonjesta which is used for managing nausea and vomiting of pregnancy in non-responsive women., has several other brand drugs in the same treatment category and using the same active ingredient (Doxylamine Succinate; Pyridoxine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Duchesnay
Diclegis

(uses Doxylamine Succinate; Pyridoxine Hydrochloride)

Used for treating nausea and vomiting of pregnancy in women who do not respond to conservative management.

Apart from brand drugs containing the same ingredient, some generics have also been filed for Doxylamine Succinate; Pyridoxine Hydrochloride, Bonjesta's active ingredient. Check the complete list of approved generic manufacturers for Bonjesta





About Bonjesta

Bonjesta is a drug owned by Duchesnay Inc. It is used for managing nausea and vomiting of pregnancy in non-responsive women. Bonjesta uses Doxylamine Succinate; Pyridoxine Hydrochloride as an active ingredient. Bonjesta was launched by Duchesnay in 2016.

Approval Date:

Bonjesta was approved by FDA for market use on 07 November, 2016.

Active Ingredient:

Bonjesta uses Doxylamine Succinate; Pyridoxine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Doxylamine Succinate; Pyridoxine Hydrochloride ingredient

Treatment:

Bonjesta is used for managing nausea and vomiting of pregnancy in non-responsive women.

Dosage:

Bonjesta is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
20MG;20MG TABLET, EXTENDED RELEASE Prescription ORAL